BioMarin Pharmaceutical (BMRN) — insider trading
Health Care
BioMarin Pharmaceutical (BMRN) has 12 reported SEC Form 4 insider transactions in our data, including 1 open-market sale among the most recent 12 (latest 2026-06-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | ANDERSON ELIZABETH M | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Bodem Barbara W. | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-06-02 | CLARK IAN T | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Dere Willard H | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Enyedy Mark J | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-06-02 | HOMBACH ROBERT J. | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Ho Maykin | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Walbert Timothy P | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Countouriotis Athena | Director | Grant / award / vesting | 7,490 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Hubbard Cristin | Officer (EVP, Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 2,318 | $50.20 | $116.4K | Form 4 |
| 2026-05-07 | Friberg Gregory R | Officer (EVP, Chief R&D Officer) | Open-market sale | 3,281 | $53.85 | $176.7K | Form 4 |
| 2026-03-18 | Davis George Eric | Officer (EVP, Chief Legal Officer) | Shares withheld for taxes / exercise cost | 1,273 | $56.05 | $71.4K | Form 4 |
Ask the chat about BMRN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BioMarin Pharmaceutical (BMRN).
Last updated 2026-06-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.